Middle Atlantic Regional Center for Excellence for Biodefense and Emerging Infect
Project Number5U54AI057168-10
Contact PI/Project LeaderLEVINE, MYRON MAX
Awardee OrganizationUNIVERSITY OF MARYLAND BALTIMORE
Description
Abstract Text
The Middle Atlantic Regional Center of Excellence (MARCE) proposes to harness and focus the extraordinary wealth of scientific ingenuity, innovation, and investigator experience that resides within the institutions in our region to support research on an array of NIAID Emerging and Category A-C pathogens. The over-arching theme for the MARCE Research Programs is "Emerging pathogen-host interactions". Under this theme, we propose six Research Programs that are centered on the study of: specific emerging viruses (Programs I and II); targeted respiratory and enteric bacterial pathogens (Programs III and IV, respectively); Select or Emerging Agent toxins (Program V); and, development of novel diagnostic technologies to detect these chosen organisms or toxins (Program VI). Each Program contains five or six highly collaborative Research Projects from investigators at three or more institutions within the Middle Atlantic region. In all, ten different institutions in the MARCE are home to one or more of the Research Projects, and six additional institutions host collaborators on these MARCE projects, training activities, or core resources. That the Programs were intentionally founded on cross-institutional collaborations reflects the high degree of inclusiveness fostered by MARCE. As during our first funding period, we will pursue a balanced research agenda that includes a mix of very basic research, clear translational research involving potential products and clinical research that all aim, ultimately, to result in new or improved therapeutic, preventive or diagnostic products. Our Research Programs are supported by an array of training activities including a series of novel courses that were exceptionally well attended during our first funding period. A robust Career Development Program will bring a cadre of bright, motivated, young scientists into the broad area of biodefense and emerging infectious diseases research. Our Developmental Research Plan is designed to incorporate new projects, investigators, and institutions into the existing MARCE program and to emphasize innovative concepts, new technologies, and "high-risk" opportunities that demonstrate potential for "high-yield" novel results in the area of biodefense and emerging infectious diseases research. When coupled with our rigorous internal and external evaluation system that has resulted in continual replacement of projects to address our strategic mission over the past five years, the MARCE will represent an innovative, vibrant and flexible research program well suited to the translation of basic research on emerging pathogen-host interactions into therapeutic and vaccine targets and products.
Public Health Relevance Statement
The MARCE proposes to harness and focus the extraordinary wealth of scientific ingenuity, innovation, and investigator experience that resides within the institutions in our region to support research on an array of NIAID Emerging and Category A-C pathogens. Scientific information and translational research capacity resulting from these collective efforts will ultimately result in new or improved therapeutic, preventive or diagnostic products for the benefit of public heath.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAreaBasic ScienceCategoriesCenters of Research ExcellenceClinical ResearchCollaborationsCoupledDevelopmentDiagnosticEmerging Communicable DiseasesEnteralEquilibriumEvaluationFosteringFundingHome environmentInfectious Diseases ResearchInstitutionMissionNational Institute of Allergy and Infectious DiseaseOrganismPreventiveResearchResearch PersonnelResearch Project GrantsResearch SupportResourcesScientistSeriesSystemTechnologyTherapeuticToxinTraining ActivityTranslational ResearchTranslationsVirusbiodefensecareer developmentdesignexperienceflexibilityhigh riskimprovedinnovationnew technologynovelnovel diagnosticspathogenprogramsrespiratorytherapeutic vaccine
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
188435911
UEI
Z9CRZKD42ZT1
Project Start Date
04-September-2003
Project End Date
28-February-2015
Budget Start Date
01-March-2013
Budget End Date
28-February-2015
Project Funding Information for 2013
Total Funding
$6,823,026
Direct Costs
$6,617,100
Indirect Costs
$938,913
Year
Funding IC
FY Total Cost by IC
2013
National Institute of Allergy and Infectious Diseases
$6,823,026
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U54AI057168-10
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54AI057168-10
Patents
No Patents information available for 5U54AI057168-10
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54AI057168-10
Clinical Studies
No Clinical Studies information available for 5U54AI057168-10
News and More
Related News Releases
No news release information available for 5U54AI057168-10
History
No Historical information available for 5U54AI057168-10
Similar Projects
No Similar Projects information available for 5U54AI057168-10